Metastatic or Refractory Soft Tissue Sarcomas and Metronomic Cyclophosphamide: Further Assessment of Efficacy and Safety (MeRCY)

Centre Hospitalier Universitaire de Besancon

Status: Completed

Conditions: Sarcoma; Soft Tissue Sarcoma

Study type: Observational

Funder types: Other

Identifiers

NCT06216990

2022/704

Details and patient eligibility

About

Metronomic Cyclophosphamide's use in monotherapy as a palliative treatment against non-resectable and metastatic Soft Tissue Sarcomas relies on small retrospective cohorts' data.

Current litterature needs external validation of its efficacy and safety profile in these settings of usually frail patients.

The investigators assessed further data and aimed to identify predictive factors of metronomic cyclophosphamide impact in metastatic Soft Tissue Sarcomas.

Enrollment: 60 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients over 18
• with inoperable or metastatic Soft Tissue Sarcoma
• treated with Metronomic Cyclophosphamide
• in 3 cancer care institutions located in 2 French regions (Bourgogne and Franche-Comté)
• between January 2005 and December 2021

Exclusion criteria

• patients with bone, chondral sarcomas, desmoid, or gastrointestinal stromal tumors